The nasal spray Neffy is the first non-injectable epinephrine to treat the life-threatening allergic response ARS Pharmaceuticals, Inc. The first-ever needle-free alternative to the EpiPen and similar ...

ARS Pharma had high hopes that the FDA on Tuesday would approve its flagship product, a needle-free treatment for adults and children with severe allergic reactions. But instead, the drugmaker was set ...

The Food and Drug Administration has just approved a first-of-its-kind needle-free alternative to EpiPens or epinephrine autoinjectors. Neffy, a nasal spray that delivers a dose of epinephrine, is the ...

The Food and Drug Administration has approved ARS Pharmaceuticals’ nasal spray as the first needle-free emergency treatment for potentially fatal allergic reactions, the agency said on Friday. The ...

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...

FDA advisors recommended that the agency approve an intranasal epinephrine product for type I allergic reactions, including anaphylaxis, despite concerns about the lack of clinical efficacy data. On ...

Anaphylaxis is a severe allergic reaction that can quickly become life threatening. It can affect breathing, digestion, and circulation within seconds of exposure. Symptoms can include wheezing, chest ...

Biphasic anaphylaxis involves a second anaphylactic reaction that happens after the first has been successfully treated. This may occur up to 72 hours after the initial reaction. Anaphylaxis is a ...

Anaphylaxis can cause severe itching, difficulty breathing, fainting, and abdominal pain. These symptoms usually begin about 30 minutes after coming into contact with an allergy trigger. First, call ...

EURneffy ® 2 mg nasal spray offers a simple-to-use, 3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed ...